July 13, 2006 -- The FDA approved Atripla, an all-in-one HIV therapy developed by Bristol-Myers Squibb and Gilead; J&J released positive data on a new schizophrenia drug; Acadia reported good early results on another schizophrenia compound; Corautus said the FDA lifted its clinical hold on an anti-angina therapy; Archemix signed a $350 million deal to develop autoimmune therapies for Elan; and the FDA told Nastech that its nasally-delivered osteoporosis drug is not approvable.The Centient Biotech 200™ lost 46 points to end at 3570, a 1.27% drop. More details...
